Development of an effective predictive screening tool for prostate cancer using the ClarityDX machine learning...

Area of Science:

• Oncology
• Biomarkers
• Machine Learning in Medicine

Background:

• Prostate-specific antigen (PSA) screening for prostate cancer (PCa) lacks specificity, leading to overdiagnosis and overtreatment of non-clinically significant PCa (csPCa).
• Distinguishing between csPCa and non-csPCa early is crucial to avoid unnecessary invasive procedures like prostate biopsies.

Purpose of the Study:

• To develop and validate an advanced machine learning-based blood test, ClarityDX Prostate, for accurate risk stratification of csPCa.
• To assess the utility of ClarityDX Prostate in reducing unnecessary prostate biopsies.

Main Methods:

• An optimized machine learning platform (ClarityDX) was integrated with blood-based biomarkers and clinical data from a 3448-patient cohort.
• A predictive model, ClarityDX Prostate, was developed to stratify patients' risk of csPCa.
• The test's performance was evaluated in a validation cohort, assessing sensitivity, specificity, positive predictive value, and negative predictive value.

Main Results:

• ClarityDX Prostate demonstrated 95% sensitivity and 91% negative predictive value for high-risk cancer at a ≥25% threshold.
• The test could potentially avoid up to 35% of unnecessary prostate biopsies.
• ClarityDX Prostate exhibited higher accuracy in predicting csPCa risk compared to PSA alone and existing risk calculators.

Conclusions:

• ClarityDX Prostate offers a more accurate method for identifying clinically significant prostate cancer risk than current screening methods.
• Implementing ClarityDX Prostate as a reflex test for elevated PSA levels can aid clinical decision-making regarding prostate biopsies.
• This AI-driven approach has the potential to significantly improve prostate cancer diagnosis and patient management.